ASKG915 for advanced solid tumors that stopped responding
Treatments studied
Part of Cancer clinical trials.
This early-stage study tests ASKG915, a new treatment, for people with advanced solid cancers that are no longer responding to standard care (or don’t have standard options). If you may qualify, you’d be screened with recent health tests to check safety and eligibility, and then receive the study drug.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an advanced solid cancer confirmed by a lab test (biopsy or body fluid sample) that is no longer responding to standard treatment, or there is no standard treatment
- Your day-to-day functioning is good enough (ECOG 0–2), and you have at least 3 months to live
- You can have the required lab tests, and your results must meet the trial’s thresholds
- You have not had cancer treatment in the 4 weeks before starting the study drug
- You have no brain or meninges (covering of the brain) cancer spread, and you do not have certain serious heart/stroke problems
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug combination for people with advanced solid tumors that have not responded to other treatments. It aims to see if the combination is safe and effective.
This trial tests a new daily pill that targets a protein helping cancer cells divide. It may stop tumors from growing in people with advanced or metastatic cancer that has returned or stopped responding to standard treatments, including some types of ovarian, lung, and other solid tumors.
This trial tests a new combination of drugs for advanced solid tumors. It may help if your cancer has not responded to other treatments, and the goal is to see how safe and effective this new approach is.
This trial tests a new drug called SHR-A2102, alone or with other cancer treatments, for people with advanced solid tumors that haven't responded well to standard therapies. It aims to see if the drug can shrink tumors or slow their growth.
This trial tests a new drug called QLC5508, given in combination with other treatments, for people with advanced solid tumors that have stopped responding to standard therapy or who haven't had treatment yet. The goal is to see if the combination can shrink tumors or slow their growth.
This Phase 1 trial studies how safe ASKC202 is, what dose is tolerable, and whether it shows early signs of shrinking certain advanced cancers. Depending on your tumor type and prior treatments, ASKC202 may be tested alone or with another drug.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.